(2) |
Information herein is solely based on a Schedule 13G filed with the SEC on February 10, 2022. Globeways
Holdings Ltd., or Globeways is deemed to be the beneficial owner of 2,101,153 shares of common stock, with respect to which such entity reported shared voting and dispositive power over 2,101,153 shares. F2 Bioscience I 2017 Ltd., or F2 Bioscience
2017 is deemed to be the beneficial owner of 639,295 shares of common stock, with respect to which such entity reported having shared voting and dispositive power over 639,295 shares. F2 MG Ltd., or F2 MG is deemed to be the beneficial owner of
325,333 shares of common stock, with respect to which such entity reported shared voting and dispositive power over 325,333 shares. Globeways Holdings II Ltd., or Globeways II is deemed to be the beneficial owner of 1,013,334 shares of common stock,
with respect to which such entity reported having shared voting and dispositive power over 1,013,334 shares. F2-TPO Investments, LLC, or F2 TPO is deemed to be the beneficial owner of 622,175 shares of common
stock, with respect to which such entity reported having shared voting and dispositive power over 622,175 shares. F2 Bio TD, LLC, or F2 Bio is deemed to be the beneficial owner of 71,599 shares, with respect to which such entity reported having
shared voting and dispositive power over 71,599 shares. F2 MC, LLC, or F2 MC is deemed to be the beneficial owner of 214,798 shares of common stock, with respect to which such entity reported having shared voting and dispositive power over 214,798
shares. F2 GC, LLC, or F2 GC is deemed to be the beneficial owner of 104,762 shares of common stock, with respect to which such entity reported having shared voting and dispositive power over 104,762 shares. F2 Vision Management Sarl, or F2 Vision
Management is deemed to be the beneficial owner of 2,912,345 shares of common stock, with respect to which such entity reported having shared voting and dispositive power over 2,912,345 shares. F2 Vision SCS, or F2 Vision is deemed to be the
beneficial owner of 2,912,345 shares of common stock, with respect to which such entity reported having shared voting and dispositive power over 2,912,345 shares. Morana Jovan-Embiricos is deemed to be the beneficial owner of 6,279,713 shares of
common stock, with respect to which she reported having sole voting and dispositive power over 252,881 shares and shared voting and dispositive power over 6,026,832 shares. Dr. Morana Jovan-Embiricos was a member of our board of directors and
is the founding director of Globeways, which is the appointed manager of each of F2 Bioscience 2017 and F2 MG. Dr. Morana Jovan-Embiricos is also the founder of Globeways wholly-owned subsidiary Globeways II, which is the appointed
manager of F2 TPO, F2 MC, F2 GC and F2 Bio. Dr. Morana Jovan-Embiricos is also the founder of Globeways wholly-owned subsidiary F2 Vision Management, which is the appointed manager of F2 Vision. Dr. Morana Jovan-Embiricos makes
investment decisions on behalf of all such entities with respect to shares held by such entities. Dr. Morana Jovan-Embiricos expressly disclaims beneficial ownership of the securities held by F2 Bioscience 2017, F2 MG, F2 TPO, and F2 Bio, F2
MC, F2 GC and F2 Vision. The address for correspondence of Dr. Morana Jovan-Embiricos, Globeways and F2 Bioscience 2017 is 8, Rue Saint-Leger, CH 1205, Geneva, Switzerland. The address for correspondence of F2 MG is Contrada di Sassello 2, 6900
Lugano, Switzerland. The address for correspondence of Globeways II, F2 TPO, F2 Bio, F2 GC and F2 MC is 8 West 38th Street, Suite 1001, New York, NY 10018, USA, and the address for correspondence of F2 Vision and F2 Vision Management is 74, Grand-Rue, L-1660 Luxembourg. |